Loading…
TEVA-DOXYCYCLINE is a brand name for Doxycycline, supplied as a capsule. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
DOSAGE EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS. Adults The recommended dosage of oral Teva-Doxycycline Capsules / Teva- Doxycycline Tablets for the majority of susceptible infections is a single loading dose of 200 mg on the first day of treatment followed by a maintenance dosage of 100 mg once daily at the same time each day thereafter.
In the management of more severe infections (particularly chronic infections of the urinary tract), 200 mg should be given daily throughout the treatment period. Therapy should be continued for at least 24-48 hours after symptoms and fever have subsided.
It should be noted, however, that effective antibacterial levels are usually present 24 to 36 hours following discontinuance of doxycycline hyclate therapy. When used in streptococcal infections, therapy should be continued for 10 days to prevent the development of rheumatic fever or glomerulonephritis.
d. for 3 days. For treatment of uncomplicated urethral, endocervical, or vaginal infections in adults associated with Chlamydia trachomatis and Ureaplasma urealyticum: 100 mg, by mouth, twice a day for at least 10 days. No alteration in recommended dosage schedule need be made when treating patients with impaired renal function.
ADMINISTRATION Teva-Doxycycline Capsules / Teva-Doxycycline Tablets should be given with or after a meal in order to minimize the possibility of gastric upset. Antacids and iron preparations impair absorption and should not be given concomitantly to patients taking oral doxycycline hyclate.
Patients should be advised to take Teva-Doxycycline Capsules / Teva-Doxycycline Tablets with a full glass of water, to keep in orthostatic position after the administration and not to go to bed within 1-2 hours after the intake. 87 g/mol Description: Doxycycline hyclate is a yellow, hygroscopic crystalline powder, freely soluble in water and in methanol, sparingly soluble in ethanol (96 per cent), it dissolves in solutions of alkali hydroxides and carbonates.
Composition:
TEVA-DOXYCYCLINE CAPSULES: each blue, hard gelatin capsule contains: doxycycline hyclate equivalent to 100 mg of doxycycline base and non-medicinal ingredients: microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate, magnesium stearate and talc.
The capsule shell contains: gelatin, titanium oxide and FD&C blue #1, each capsule is printed with black ink. 13 TEVA-DOXYCYCLINE TABLETS: each orange film coated tablet contains doxycycline hyclate equivalent to doxycycline 100 mg.
Also contains colloidal silicon dioxide, FD&C Blue #2, FD&C Red #40, FD&C Yellow #6, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and titanium dioxide.
GASTROINTESTINAL:
As with other broad spectrum antibiotics administered orally and parenterally, gastro-intestinal disturbances such as decreased appetite, nausea, vomiting, diarrhea, glossitis, dysphagia, stomatitis, proctitis and enterocolitis, may occur, but have rarely been sufficiently troublesome to warrant discontinuation of therapy with doxycycline hyclate.
Abdominal pain, dyspepsia (heartburn/gastritis), pseudomembranous colitis, Clostridium difficile colitis and inflammatory lesions (with monilial overgrowth) in the anogenital region have also been reported. Due to oral doxycycline’s virtually complete absorption, side effects of the lower bowel, particularly diarrhea, have been infrequent.
Cases of esophagitis and esophageal ulcer, sometimes severe, in patients receiving capsule and tablet form of doxycycline hyclate have been reported (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION, INFORMATION FOR THE PATIENT).
AUTONOMIC NERVOUS SYSTEM:
Flushing HYPERSENSITIVITY: Hypersensitivity reactions consisting of urticaria, angioedema, anaphylactic reaction, anaphylactoid reaction, Henoch-Schonlein Purpura, dyspnea, hypotension, pericarditis, peripheral edema, serum sickness, tachycardia and exacerbation of systemic lupus erythematosus have been reported.
SKIN:
Maculopapular and erythematous rashes, photosensitivity reaction, photo-onycholysis, erythema multiforme, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis have been reported. Exfoliative dermatitis has also been reported but is uncommon (see WARNINGS, skin).
MUSCULO-SKELETAL:
Arthralgia and myalgia.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Doxycycline in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
DOSAGE FORMS AVAILABILITY TEVA-DOXYCYCLINE CAPSULES: 100 mg are available as yellow powder filled in size ‘1” hard gelatin capsules with opaque aqua blue cap and body, printed in black ink with ‘NOVO’ and ‘100’ on the opposing cap and body portions of the capsule, supplied in bottles of 100 and 200 TEVA-DOXYCYCLINE TABLETS: 100 mg are available as orange coloured, standard convex film coated tablets with yellow cores engraved ’‘TV’ on one side and ‘100’ on the other side, containing doxycycline hyclate equivalent to 100 mg of doxycycline, supplied in bottles of 100.
STABILITY AND STORAGE RECOMMENDATIONS:
Store bottles between 15°C and 30°C and protect from light. MICROBIOLOGY Doxycycline is a broad spectrum antibiotic and has been shown to be active in vitro against the following Gram-negative, Gram-positive and other micro-organisms: Staphylococcus aureus Klebsiella pneumoniae Staphylococcus epidermidis (albus) Streptococcus pyogenes Salmonella typhi Streptococcus faecalis Salmonella typhimurium Streptococcus pneumoniae Salmonella enteriditis Streptococcus viridans Shigella sonnei Listeria monocytogenes Shigella flexneri Corynebacterium diphtheriae Bacillus anthracis Bacillus subtilis Neisseria gonorrhoeae Neisseria catarrhalis 14 Escherichia coli Enterobacter aerogenes Pseudomonas aeruginosa Haemophilus influenzae Serratia spp.
Brucella spp. Proteus spp. Pasteurella spp. Mycoplasma pneumoniae Chlamydia trachomatis Ureaplasma urealyticum The drugs in the tetracycline class have closely similar antimicrobial spectra, and cross-resistance among them is common. SUSCEPTIBILITY TESTING The Kirby-Bauer method of disc susceptibility testing (using the 30 μg doxycycline disc) and dilution susceptibility should be interpreted according to the criteria in TABLE 1.
C. mg/L Susceptible ≥ 16 ≤ 4 Intermediate 13-15 8 Resistant ≤ 12 ≥16 PHARMACOLOGY A comparative two-way, single-dose bioavailability study was carried out in twelve adult volunteers on two 100 mg doxycycline hyclate tablet products, Teva-Doxycycline 100 mg Tablets and Vibra-Tabs 100 mg Tablets.
21 (30) […]
CENTRAL NERVOUS SYSTEM:
Headache, fontanelle bulging in infants and benign intracranial hypertension (pseudotumor cerebri) in adults. In relation to benign intracranial hypertension, symptoms included blurring of vision, scotomata and diplopia. Permanent visual loss has 10 been reported (see PRECAUTIONS).
LIVER/BILIARY:
There have been reports of hepatotoxicity (including hepatic failure, autoimmune hepatitis and cholestasis) and hepatic function abnormal. As with other tetracyclines, hepatitis, elevation of SGOT or SGPT values have been reported, the significance of which is not known.
HAEMATOLOGIC:
Hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia, leukopenia.
IMMUNE SYSTEM DISORDERS:
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) HEARING/VESTIBULAR: Tinnitus. INVESTIGATIONS (Renal Function Analyses) Blood urea increased (apparently dose related) has been reported.
UROGENITAL:
Vaginal candidiasis (see PRECAUTIONS) OTHERS: When given over prolonged periods tetracyclines have been reported to produce brown- black microscopic discolouration of the thyroid gland. Abnormalities of thyroid function have not been shown to date (see TOXICOLOGY, Subacute Toxicity).
SYMPTOMS AND TREATMENT OF OVERDOSAGE Specific information on symptoms or treatment of overdosage with doxycycline hyclate is not available. In case of overdosage, discontinue medication. Treatment, therefore, should be symptomatic and gastric lavage may be considered for overdosage with the oral preparation.
Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage. For management of suspected drug overdose contact your regional Poison Control Centre. 11 DOSAGE AND ADMINISTRATION DOSAGE EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.
Adults The recommended dosage of oral Teva-Doxycycline Capsules / Teva- Doxycycline Tablets for the majority of susceptible infections is a single loading dose of 200 mg on the first day of treatment followed by a maintenance dosage of 100 mg once daily at the same time each day thereafter.
In the management of more severe infections (particularly chronic infections of the urinary tract), 200 mg should be given daily throughout the treatment period. Therapy should be continued for at least 24-48 hours after symptoms and fever have subsided.
It should be noted, however, that effective antibacterial levels are usually present 24 to 36 hours following discontinuance of doxycycline hyclate therapy. When used in streptococcal infections, therapy should be continued for 10 days to prevent the development of rheumatic fever or glomerulonephritis.
d. for 3 days. For treatment of uncomplicated urethral, endocervical, or vaginal infections in adults associated with Chlamydia trachomatis and Ureaplasma urealyticum: 100 mg, by mouth, twice a day for at least 10 days. No alteration in recommended dosage schedule need be made when treating patients with impaired renal function.
ADMINISTRATION Teva-Doxycycline Capsules / Teva-Doxycycline Tablets should be given with or after a meal in order to minimize the possibility of gastric upset. Antacids and iron preparations impair absorption and should not be given concomitantly to patients taking oral doxycycline hyclate.
Patients should be advised to take Teva-Doxycycline Capsules / Teva-Doxycycline Tablets with a full glass of water, to keep in orthostatic position after the administration and not to go to bed within 1-2 hours after the intake. 87 g/mol Description: Doxycycline hyclate is a yellow, hygroscopic crystalline powder, freely soluble in water and in methanol, sparingly soluble in ethanol (96 per cent), it dissolves in solutions of alkali hydroxides and carbonates.
Composition:
TEVA-DOXYCYCLINE CAPSULES: each blue, hard gelatin capsule […]